AGBL2: A Potential Drug Target and Biomarker (G79841)

Target Name: AGBL2

NCBI ID: G79841

AGBL2

AGBL2: A Potential Drug Target and Biomarker

Introduction

AGBL2 (ATP/GTP-binding protein-like 2) is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. This protein plays a critical role in various cellular processes , including cell signaling, DNA replication, and protein transport. Its structural and functional domain versatility make it a very attractive drug target. In this article, we will gain an in-depth understanding of the biological functions of AGBL2, explore its potential as a drug target or biomarker, and explore its future application prospects in drug development.

biological functions

AGBL2 is a protein belonging to the TRIM family, named after its conserved ATP/GTP binding domain. The protein is composed of a single polypeptide chain, and its variable region contains multiple functional domains, including a GTP-binding domain, an ATP-binding domain, a GTP-binding domain and a DNA-binding domain.

AGBL2 plays an important role in cell signaling. In the GTP-binding domain, AGBL2 binds to GTP to form a GTP-AGBL2 complex. This complex can activate protein kinase A, leading to the activation of a series of cell signaling pathways, including cell proliferation, differentiation, migration, and apoptosis. In addition, AGBL2 also binds to DNA and participates in processes such as DNA replication and repair.

as a drug target

Because AGBL2 plays an important role in a variety of diseases, it is widely considered as a potential drug target. The expression level of AGBL2 changes in many cancers and can be used as a biomarker of tumors. For example, studies have shown that the expression level of AGBL2 is positively correlated with the prognosis of cancers such as breast, lung and ovarian cancer. In addition, AGBL2 is also closely related to the occurrence and development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and is therefore considered a potential drug target.

as biomarkers

AGBL2's role in disease diagnosis and treatment also lies in its role as a biomarker. Since AGBL2 changes in expression levels in various diseases, it can serve as a promising biomarker. For example, some studies have shown that AGBL2 expression levels can be used to predict quality of life and disease severity in patients with Parkinson's disease. In addition, AGBL2 can also be used as a screening indicator for neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.

Application prospects as a drug R&D

With in-depth research on the biological functions of AGBL2, the application prospects of AGBL2 in drug research and development are becoming increasingly broad. Currently, some companies have launched AGBL2-related drug research and development projects, aiming to develop drugs that can regulate AGBL2 expression levels to treat various diseases.

In addition, AGBL2 is also used as a target for therapeutic drugs, such as anti-tumor drugs, anti-depressant drugs, and anti-Alzheimer's disease drugs. Research on these drugs mainly focuses on treating various diseases by regulating AGBL2 expression levels.

in conclusion

AGBL2 is a protein that plays an important role in processes such as cell signaling and DNA replication. In drug development, AGBL2 is widely recognized as a potential drug target and can be used as a biomarker and drug target for the treatment of various diseases. With in-depth research on the biological functions of AGBL2, the application prospects of AGBL2 in drug research and development will be more extensive in the future.

Protein Name: AGBL Carboxypeptidase 2

Functions: Metallocarboxypeptidase that mediates deglutamylation of tubulin and non-tubulin target proteins. Catalyzes the removal of polyglutamate side chains present on the gamma-carboxyl group of glutamate residues within the C-terminal tail of tubulin protein. Specifically cleaves tubulin long-side-chains, while it is not able to remove the branching point glutamate. Also catalyzes the removal of polyglutamate residues from the carboxy-terminus of non-tubulin proteins such as MYLK

The "AGBL2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AGBL2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets